Answers are grounded in this paper and cite their sources.
We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m (2)) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.
No takes yet. Share an insight, caveat, or question.
Breccia et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: